Synthetic Cannabinoid Analog Formulation for Solid Oral Dosage
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for improved therapeutic compounds to treat disorders such as diabetes, depression, anxiety, substance addiction, pain, cancer, and autoimmune disorders associated with chronic inflammation, particularly compounds that can be synthesized and formulated as solid oral dosage forms.
Innovation Solution
Development of synthetic cannabinoid analogs with specific molecular structures, such as those represented by Formulas (I), (IA), (II), and (III), which can be administered as pharmaceutical compositions to treat various disorders, including cancer, addiction, epilepsy, anxiety, diabetes, and depression.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If natural cannabis and its constituents (THC, CBD) are used as therapeutic compounds, then therapeutic effects are achieved, but the compounds cannot be easily formulated as solid oral dosage forms and have limited synthetic availability
Solution Approach 1:
The patent modifies the molecular structure of natural cannabinoids by changing chemical parameters (introducing synthetic substituents, modifying molecular weight, adjusting functional groups) to create analogs that improve formulation properties while maintaining therapeutic activity. This allows transition from natural product extraction to synthetic chemistry with better manufacturability.
Solution Approach 2:
The patent creates synthetic copies of natural cannabinoid molecules by replicating the core cannabinoid structure and introducing analogous functional groups. These synthetic analogs (Formulas I-III) mimic the biological activity of natural THC and CBD while enabling improved formulation as solid oral dosage forms.
2Ease of manufacture
If synthetic cannabinoid analogs with modified structures are developed, then ease of manufacture and formulation are improved, but the complexity of molecular structure increases
Solution Approach 1:
The patent divides the cannabinoid molecule into distinct functional segments (core cannabinoid structure, substitutable R1-R6 groups, functional moieties) that can be independently modified. This segmentation allows systematic variation of molecular properties while maintaining overall structural recognition by cannabinoid receptors.
Solution Approach 2:
The patent creates a universal synthetic cannabinoid scaffold (Formulas I-III) that can accommodate multiple different substituents at various positions (R1-R6), allowing a single core structure to generate multiple analogs with different therapeutic profiles, pharmacokinetic properties, and formulation characteristics.
Data Source
AI summary
Cannabinoid analogs may exhibit anti-inflammatory properties such as by inhibition of cannabinoid type 2 (CB2) receptors. Pharmaceutical compositions comprising the cannabinoid analogs may be used to treat various diseases and conditions in mammals, including diabetes, cancer, pain, anxiety, addiction, epilepsy, depression, or Alzheimer's disease.